Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
This article was originally published in PharmAsia News
Executive SummaryNovartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan
You may also be interested in...
Mexico published its final biosimilars guidelines the same day as India, both drawing from WHO standards.